A distinct serum protein pattern in patients with paranoid schizophrenia

Irina V. Alekseeva, Nadezhda A. Timofeyeva, Svetlana A. Ivanova, German G. Simutkin, Arkadiy V. Semke, Innokentiy S. Losenkov, Nikolay A. Bokhan, Olga S. Fedorova, Alexander A. Chernonosov

Research output: Contribution to journalArticle

Abstract

Introduction: Schizophrenia is a chronic mental illness, whose aetiology is still unclear; therefore, information about differences in serum protein patterns may improve the understanding of the pathophysiology of schizophrenia. The goal of this study was to use the proteomic approach to identify altered protein levels in the serum samples from patients with schizophrenia. Methods: Blood was collected from 10 patients with paranoid schizophrenia and 10 healthy volunteers matched by sex and age. Serum proteins were isolated by 2D gel electrophoresis. Proteins with altered levels were identified by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. Results: We uncovered major changes in the expression of such proteins as apolipoproteins of classes A4 and C3, transthyretin (TTR) and serum amyloid A1. An increase in expression was found only for apolipoprotein A4, whereas the expression of apolipoprotein C3, TTR and serum amyloid A1 was decreased. The observed differences in the expression of serum proteins (TTR and serum amyloid) are in good agreement with the results obtained by other research groups during analyses of cerebrospinal fluid or post-mortem brain tissues by other methods. Conclusion: Such alterations of the expression of these proteins may indicate problems with regulation, for example, in the synthesis. On the other hand, the altered protein expression may simply reflect the pathophysiological status of patients, where these proteins could be candidates for biomarkers. Further research is needed to confirm the significance of the altered levels of these proteins in the pathogenesis of schizophrenia and to determine their suitability as biomarkers of schizophrenia.

Original languageEnglish
Pages (from-to)304-311
Number of pages8
JournalPhysiology and Pharmacology (Iran)
Volume21
Issue number4
Publication statusPublished - 1 Dec 2017

Fingerprint

schizophrenia
etiology
mental illness
chronic illness
Schizophrenia
Protein
brain
candidacy
regulation
Group

Keywords

  • Biomarker
  • Proteomics
  • Psychiatric disorder
  • Schizophrenia

ASJC Scopus subject areas

  • Language and Linguistics
  • Linguistics and Language

Cite this

Alekseeva, I. V., Timofeyeva, N. A., Ivanova, S. A., Simutkin, G. G., Semke, A. V., Losenkov, I. S., ... Chernonosov, A. A. (2017). A distinct serum protein pattern in patients with paranoid schizophrenia. Physiology and Pharmacology (Iran), 21(4), 304-311.

A distinct serum protein pattern in patients with paranoid schizophrenia. / Alekseeva, Irina V.; Timofeyeva, Nadezhda A.; Ivanova, Svetlana A.; Simutkin, German G.; Semke, Arkadiy V.; Losenkov, Innokentiy S.; Bokhan, Nikolay A.; Fedorova, Olga S.; Chernonosov, Alexander A.

In: Physiology and Pharmacology (Iran), Vol. 21, No. 4, 01.12.2017, p. 304-311.

Research output: Contribution to journalArticle

Alekseeva, IV, Timofeyeva, NA, Ivanova, SA, Simutkin, GG, Semke, AV, Losenkov, IS, Bokhan, NA, Fedorova, OS & Chernonosov, AA 2017, 'A distinct serum protein pattern in patients with paranoid schizophrenia', Physiology and Pharmacology (Iran), vol. 21, no. 4, pp. 304-311.
Alekseeva IV, Timofeyeva NA, Ivanova SA, Simutkin GG, Semke AV, Losenkov IS et al. A distinct serum protein pattern in patients with paranoid schizophrenia. Physiology and Pharmacology (Iran). 2017 Dec 1;21(4):304-311.
Alekseeva, Irina V. ; Timofeyeva, Nadezhda A. ; Ivanova, Svetlana A. ; Simutkin, German G. ; Semke, Arkadiy V. ; Losenkov, Innokentiy S. ; Bokhan, Nikolay A. ; Fedorova, Olga S. ; Chernonosov, Alexander A. / A distinct serum protein pattern in patients with paranoid schizophrenia. In: Physiology and Pharmacology (Iran). 2017 ; Vol. 21, No. 4. pp. 304-311.
@article{619f0a2e66da4044b89cbedf268c08b5,
title = "A distinct serum protein pattern in patients with paranoid schizophrenia",
abstract = "Introduction: Schizophrenia is a chronic mental illness, whose aetiology is still unclear; therefore, information about differences in serum protein patterns may improve the understanding of the pathophysiology of schizophrenia. The goal of this study was to use the proteomic approach to identify altered protein levels in the serum samples from patients with schizophrenia. Methods: Blood was collected from 10 patients with paranoid schizophrenia and 10 healthy volunteers matched by sex and age. Serum proteins were isolated by 2D gel electrophoresis. Proteins with altered levels were identified by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. Results: We uncovered major changes in the expression of such proteins as apolipoproteins of classes A4 and C3, transthyretin (TTR) and serum amyloid A1. An increase in expression was found only for apolipoprotein A4, whereas the expression of apolipoprotein C3, TTR and serum amyloid A1 was decreased. The observed differences in the expression of serum proteins (TTR and serum amyloid) are in good agreement with the results obtained by other research groups during analyses of cerebrospinal fluid or post-mortem brain tissues by other methods. Conclusion: Such alterations of the expression of these proteins may indicate problems with regulation, for example, in the synthesis. On the other hand, the altered protein expression may simply reflect the pathophysiological status of patients, where these proteins could be candidates for biomarkers. Further research is needed to confirm the significance of the altered levels of these proteins in the pathogenesis of schizophrenia and to determine their suitability as biomarkers of schizophrenia.",
keywords = "Biomarker, Proteomics, Psychiatric disorder, Schizophrenia",
author = "Alekseeva, {Irina V.} and Timofeyeva, {Nadezhda A.} and Ivanova, {Svetlana A.} and Simutkin, {German G.} and Semke, {Arkadiy V.} and Losenkov, {Innokentiy S.} and Bokhan, {Nikolay A.} and Fedorova, {Olga S.} and Chernonosov, {Alexander A.}",
year = "2017",
month = "12",
day = "1",
language = "English",
volume = "21",
pages = "304--311",
journal = "Physiology and Pharmacology",
issn = "1735-0581",
publisher = "Neuroscience Research Center",
number = "4",

}

TY - JOUR

T1 - A distinct serum protein pattern in patients with paranoid schizophrenia

AU - Alekseeva, Irina V.

AU - Timofeyeva, Nadezhda A.

AU - Ivanova, Svetlana A.

AU - Simutkin, German G.

AU - Semke, Arkadiy V.

AU - Losenkov, Innokentiy S.

AU - Bokhan, Nikolay A.

AU - Fedorova, Olga S.

AU - Chernonosov, Alexander A.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Introduction: Schizophrenia is a chronic mental illness, whose aetiology is still unclear; therefore, information about differences in serum protein patterns may improve the understanding of the pathophysiology of schizophrenia. The goal of this study was to use the proteomic approach to identify altered protein levels in the serum samples from patients with schizophrenia. Methods: Blood was collected from 10 patients with paranoid schizophrenia and 10 healthy volunteers matched by sex and age. Serum proteins were isolated by 2D gel electrophoresis. Proteins with altered levels were identified by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. Results: We uncovered major changes in the expression of such proteins as apolipoproteins of classes A4 and C3, transthyretin (TTR) and serum amyloid A1. An increase in expression was found only for apolipoprotein A4, whereas the expression of apolipoprotein C3, TTR and serum amyloid A1 was decreased. The observed differences in the expression of serum proteins (TTR and serum amyloid) are in good agreement with the results obtained by other research groups during analyses of cerebrospinal fluid or post-mortem brain tissues by other methods. Conclusion: Such alterations of the expression of these proteins may indicate problems with regulation, for example, in the synthesis. On the other hand, the altered protein expression may simply reflect the pathophysiological status of patients, where these proteins could be candidates for biomarkers. Further research is needed to confirm the significance of the altered levels of these proteins in the pathogenesis of schizophrenia and to determine their suitability as biomarkers of schizophrenia.

AB - Introduction: Schizophrenia is a chronic mental illness, whose aetiology is still unclear; therefore, information about differences in serum protein patterns may improve the understanding of the pathophysiology of schizophrenia. The goal of this study was to use the proteomic approach to identify altered protein levels in the serum samples from patients with schizophrenia. Methods: Blood was collected from 10 patients with paranoid schizophrenia and 10 healthy volunteers matched by sex and age. Serum proteins were isolated by 2D gel electrophoresis. Proteins with altered levels were identified by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. Results: We uncovered major changes in the expression of such proteins as apolipoproteins of classes A4 and C3, transthyretin (TTR) and serum amyloid A1. An increase in expression was found only for apolipoprotein A4, whereas the expression of apolipoprotein C3, TTR and serum amyloid A1 was decreased. The observed differences in the expression of serum proteins (TTR and serum amyloid) are in good agreement with the results obtained by other research groups during analyses of cerebrospinal fluid or post-mortem brain tissues by other methods. Conclusion: Such alterations of the expression of these proteins may indicate problems with regulation, for example, in the synthesis. On the other hand, the altered protein expression may simply reflect the pathophysiological status of patients, where these proteins could be candidates for biomarkers. Further research is needed to confirm the significance of the altered levels of these proteins in the pathogenesis of schizophrenia and to determine their suitability as biomarkers of schizophrenia.

KW - Biomarker

KW - Proteomics

KW - Psychiatric disorder

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85041208936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041208936&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 304

EP - 311

JO - Physiology and Pharmacology

JF - Physiology and Pharmacology

SN - 1735-0581

IS - 4

ER -